Circular RNA vaccines have emerged as a promising tool in disease prevention and treatment, offering advantages over traditional linear mRNA vaccines in terms of stability, immunogenicity, and ease of manufacturing. The biogenesis and functions of circRNAs have rapidly unfolded, paving the way for their application as vaccines. These circular RNA vaccines, incorporating internal ribosome entry sites and open reading frames, present a safer and more stable approach to RNA-based vaccination. However, despite their potential, circRNA vaccines are still in the early stages of development, requiring further optimization, delivery methods, and evaluation for broader applications in disease prevention and treatment.
The history of circRNA discovery dates back to the 1970s, with subsequent advancements in sequencing technologies leading to the identification of circRNAs in the mammalian transcriptome. These molecules have been found to have diverse functions, including acting as miRNA sponges and guiding protein synthesis. The in vitro synthesis of circRNAs has opened up possibilities for their use in therapeutic applications. Recent breakthroughs have demonstrated the efficacy of engineered circRNAs in triggering adaptive immune responses and therapeutic effects in diseases like COVID-19 and melanoma.
The preparation of circRNA vaccines involves a series of steps, including design, synthesis, purification, entrapment, safety evaluation, manufacturing, and clinical trials. The design of linear RNA precursors is crucial for efficient circularization, translation initiation, and minimizing immunogenicity. Elements like internal ribosome entry sites, open reading frames, and nucleotide modifications play key roles in enhancing translation efficiency and reducing immune responses. The optimization of these elements and the incorporation of specific motifs can improve the performance of circRNA vaccines.
Scaling up the production of circRNA vaccines requires careful attention to factors such as homology arms, spacer sequences, and nucleotide modifications to enhance circularization efficiency and reduce immunogenicity. In vitro transcription methods, chemical ligation, enzymatic ligation, and ribozyme ligation are commonly used techniques for circularizing linear RNA precursors. Each method has its advantages and limitations in terms of efficiency and complexity, necessitating a tailored approach based on specific vaccine requirements.
As circRNA vaccines progress towards wider application, addressing challenges related to scale-up, manufacturing efficiency, and quality control will be crucial. Ensuring batch-to-batch consistency, optimizing purification processes, and streamlining delivery methods are key considerations for successful large-scale production. By leveraging advances in biotechnology and molecular medicine, circRNA vaccines hold immense potential for revolutionizing disease prevention and treatment strategies in the future.
Key Takeaways:
– CircRNA vaccines offer stability, immunogenicity, and scalability advantages over traditional linear mRNA vaccines.
– Designing linear RNA precursors with optimized elements is essential for efficient circRNA vaccine production.
– Scaling up circRNA vaccine manufacturing requires addressing challenges in circularization efficiency, purification, and delivery methods.
– Advances in biotechnology and molecular medicine are driving the development of circRNA vaccines for broader applications in disease prevention and treatment.
Tags: adjuvants, vaccine production, viral vectors, biosafety, secretion, formulation, capillary electrophoresis, clinical trials, yeast, regulatory
Read more on pmc.ncbi.nlm.nih.gov